A Phase 2 interventional study of Teclistamab and Daratumumab and Hyaluronidase-fihj in Amyloid Light-chain Amyloidosis, sponsored by Rajshekhar Chakraborty, MD. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Rajshekhar Chakraborty, MD · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies in Immunoglobulin Light-chain Amyloidosis with a site in United States — 23 open to participants now, 35 under way, 3 of them phase 3. Immunoglobulin Light-chain Amyloidosis · United States.
Among the 151 studies in Immunoglobulin Light-chain Amyloidosis with a site in United States, this one is the 76th largest by planned enrollment of the 114 interventional ones that give a count, is one of 2 that started in 2025, is one of 49 in phase 2, reaches primary completion later than 30 of the 34 other live ones, and was the 146th registered.
239 studies on the registry are indexed under Immunoglobulin Light-chain Amyloidosis; 63 are open to participants now.
Browse Immunoglobulin Light-chain Amyloidosis studies →23 of the 151 studies in Immunoglobulin Light-chain Amyloidosis with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
GlaxoSmithKline · Sites in United States, Australia, United Kingdom
Ages 18+
Alexion Pharmaceuticals, Inc. · Sites in United States, Canada, United Kingdom
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Australia, Israel and 2 more countries
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Immunoglobulin Light-chain Amyloidosis studies recruiting now, 34 (69%) set no upper age limit and 3 (6%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 65 · Phase 3 19
First in 1991; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 39 across 169 interventional studies indexed under Immunoglobulin Light-chain Amyloidosis.
Median enrollment 38 across the 114 interventional studies, 153 across the 19 observational. Of the 111 that completed or were terminated, 42 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 151 have an industry lead sponsor. The 10 most frequent:
Rajshekhar Chakraborty, MD is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Rajshekhar Chakraborty, MD has 1 study filed under Immunoglobulin Light-chain Amyloidosis — fewer than ten, so there is no comparison to draw.
9 of the studies in Immunoglobulin Light-chain Amyloidosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06097832Nexcella Inc.Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis | 2026-12 |
| NCT05951816University of Tennessee Graduate School of MedicineA Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis | 2026-12 |
| NCT04270175Weill Medical College of Cornell UniversityDaratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab | 2027-01 |
| NCT05145816University of Texas Southwestern Medical CenterPhase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis | 2027-03-01 |
| NCT06420167Barbara Ann Karmanos Cancer InstituteDapagliFLOzin in Renal AL Amyloidosis (FLORAL) | 2027-04 |
Add all 9 to your calendar (.ics) → With an account.
Among the 151 studies in Immunoglobulin Light-chain Amyloidosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis.
The study treatment is divided into cycles (C) and each cycle is 28 days (D). Study treatment is expected to last 6 months.
The purpose of this study is to assess the effectiveness and safety of teclistamab-daratumumab combination in newly diagnosed AL amyloidosis. The study aims to evaluate whether this combination is able to effectively decrease the level of toxic amyloid-producing light chains circulating in the participants' blood, with the overarching goal of avoiding organ damage, improving organ function, and prolonging life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Measurable hematologic disease, defined as one of the following:
Pre-treatment clinical laboratory values meeting the following criteria during the screening phase:
For men: Agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm.
Exclusion Criteria:
Patients meeting criteria for symptomatic multiple myeloma by any one of the following: (a) Lytic lesions on imaging (Skeletal survey, whole body CT or MRI, or PET/CT) (b) Plasmacytoma, (c) Hypercalcemia without any alternate etiology, (d) Bone marrow plasma cell infiltrate of greater than 60%.
Patients with involved/uninvolved serum FLC ratio>100 as the sole myeloma-defining event will be allowed.
Evidence of significant cardiovascular conditions as specified below:
History of other that could affect compliance with the protocol or interpretation of results.
Patients with a history of curatively treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix, breast cancer, or Hodgkin's Lymphoma are generally eligible. Patients with a malignancy that has been treated, but not with curative intent, will be excluded, unless the malignancy has been in remission without treatment for ≥ 2 years prior to enrollment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants in this study will receive teclistamab and daratumumab.
Drug: Teclistamab · Drug: Daratumumab and Hyaluronidase-fihj
Teclistamab is a T-cell redirecting bispecific antibody (BsAb) targeting CD3 on T-cells and B-cell maturation antigen (BCMA) on plasma cells.
Also known as: TECVAYLI, teclistamab-cqyv
Drug page: Daratumumab and Hyaluronidase-fihjStudies of Daratumumab and Hyaluronidase-fihjDaratumumab and Hyaluronidase-fihj pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Daratumumab is an monoclonal antibody that targets the CD38 protein on the surface of myeloma cells.
Also known as: DARZALEX FASPRO, Daratumumab
Hematologic Complete Response (Heme-CR) rate
Heme-CR will be defined as: involved free light-chain level less than the upper limit of the normal range with negative serum and urine immunofixation; normalization of the uninvolved free light-chain level or free light-chain ratio will not be required to determine a complete response.
Time frame: 6 months from treatment initiation
Minimal Residual Disease (MRD) negativity rate by Free Light Chain Mass Spectrometry (FLC-MS) in serum
Secondary outcome is to assess the rate of minimal residual disease (MRD)-negativity and sustained MRD-negativity with Teclistamab-Daratumumab
Time frame: 1 month, 3 months, 6 months, and 18 months
MRD-negativity rate by multiparameter flow cytometry (MFC) in bone marrow
The MRD-negativity rate by 6 and 18 months will be reported descriptively.
Time frame: 6 months and 18 months
Time to heme-CR
Time to heme-CR will be calculated from the day of treatment initiation (C1D0), and will be reported as median (range).
Time frame: Day 1 of each cycle, and every 6 weeks after treatment cessation (up to 1 year)
Major organ deterioration-progression-free survival (MOD-PFS) rate
MOD-PFS will be calculated as a time-to-event endpoint using Kaplan-Meier method.
Time frame: From Cycle 2 to Cycle 6 Day 1 (Each cycle is 28 days), End of treatment visit (up to 6 months from treatment initiation), and up to 18 months from treatment initiation
Overall survival rate
Overall survival frequency from initiation of study drug, including cause of death for patients who die on study
Time frame: Through study completion, up to 18 months from treatment initiation
Frequency of Cytokine Release Syndrome (CRS)
Frequency of CRS (all-grade and grade ≥3) events
Time frame: Throughout Cycle 1 (each cycle is 28 days), Day 0, Day 1, Day 3, Day 8, Day 15, Day 22; Throughout Cycle 2 and Cycle 6 on Day 1 and Day 15; End of treatment visit (up to 6 months from treatment initiation), Post treatment follow-up (up to 18 months)
Rate of infections
Frequency rate of infections (all-grade and grade ≥3) will be reported descriptively.
Time frame: Throughout Cycle 1 (each cycle is 28 days), Day 0, Day 1, Day 3, Day 8, Day 15, Day 22; Throughout Cycle 2 and Cycle 6 on Day 1 and Day 15; End of treatment visit (up to 6 months from treatment initiation), Post treatment follow-up (up to 18 months)
Number of participants with a heart response after treatment
Heart response is defined as N-terminal pro Brain Natriuretic Peptide (NT-ProBNP) response (\>30% and \>300 ng/l decrease in subjects with baseline NT-proBNP\>650 ng/l) or New York Heart Association (NYHA) class response (\>2 class decrease in subjects with baseline NYHA class 3 or 4)
Time frame: 6 months and 18 months
Number of No Responses in the heart after treatment
No response in the heart is defined as ≤30% reduction in NT-proBNP from baseline
Time frame: 6 months and 18 months
Number of Partial Responses (PR) in participants who experienced a heart response after treatment
Partial Response in the heart is defined as 31-60% reduction in NT-proBNP from baseline.
Time frame: 6 months and 18 months
Number of Very Good Partial Responses (VGPR) in participants who experienced a heart response after treatment
VGPR in the heart is defined as \>60% reduction in NT-proBNP from baseline to a nadir of \>350 ng/L
Time frame: 6 months and 18 months
Number of Complete Response (CR) in participants who experienced a heart response after treatment
Complete Response in the heart is defined as Nadir NT-proBNP≤350 ng/L
Time frame: 6 months and 18 months
Number of participants with heart progression after treatment
Heart progression is defined as NT-proBNP progression (\>30% and \>300 ng/l increase) or cardiac troponin progression (\>33% increase) or ejection fraction progression (\>10% decrease). Subjects with progressive worsening renal function cannot be scored for NT-proBNP progression.
Time frame: 6 months and 18 months
Number of participants with a kidney response after treatment
Kidney response is defined as 50% decrease (at least 0.5 g/day) of 24-h urine protein (urine protein must be \>0.5g/day pretreatment). Creatinine and creatinine clearance must not worsen by 25% over baseline.
Time frame: 6 months and 18 months
Number of No Responses in the kidneys after treatment
No response in the kidneys is defined as ≤30% reduction in proteinuria from baseline
Time frame: 6 months and 18 months
Number of Partial Responses (PR) in participants who experienced a kidney response after treatment
Partial Response in the kidneys is defined as 31-60% reduction in proteinuria from baseline
Time frame: 6 months and 18 months
Number of Very Good Partial Responses (VGPR) in participants who experienced a kidney response after treatment
VGPR in the kidneys is defined as \>60% reduction in proteinuria from baseline level to a nadir level \>200 mg/24 hours
Time frame: 6 months and 18 months
Number of Complete Response (CR) in participants who experienced a kidney response after treatment
Complete Response in the kidneys is defined as Nadir proteinuria ≤200 mg/24 hours
Time frame: 6 months and 18 months
Number of participants with kidney progression after treatment
Kidney progression is defined as 50% increase (at least 1 g/day) of 24-h urine protein to \>1 g/day or 25% worsening of serum creatinine or creatinine clearance.
Time frame: 6 months and 18 months
Number of participants with liver response after treatment
Liver response is defined as 50% decrease in abnormal alkaline phosphatase value.
Time frame: 6 months and 18 months
Number of No Responses in the liver after treatment
No response in the liver is defined as ≤30% reduction in alkaline phosphatase (ALP) from baseline.
Time frame: 6 months and 18 months
Number of Partial Responses (PR) in participants who experienced liver response after treatment
Partial Response in the liver is defined as 31-60% reduction in ALP from baseline.
Time frame: 6 months and 18 months
Number of Very Good Partial Responses (VGPR) in participants who experienced liver response after treatment
VGPR in the liver is defined as \>60% reduction in ALP from baseline to a nadir \>2x lower limit of normal (LLN)
Time frame: 6 months and 18 months
Number of Complete Response (CR) in participants who experienced liver response after treatment
Complete Response in the liver is defined as Nadir ALP ≤2X LLN
Time frame: 6 months and 18 months
Number of participants with liver progression after treatment
Liver progression is defined as 50% increase of ALP from nadir value
Time frame: 6 months and 18 months
Hematologic event-free survival (Heme-EFS)
Heme-EFS will be calculated as a time-to-event endpoint using Kaplan-Meier method.
Time frame: Throughout Cycle 2 and Cycle 6 (each cycle is 28 days) on Day 1; End of treatment visit (up to 6 months from treatment initiation), Post treatment follow-up (up to 18 months from treatment initiation)
CD4 cell count
CD4 cells will be measured in participants before and after treatment.
Time frame: Baseline until 18 months from treatment initiation
CD8 cell count
CD8 cells will be measured in participants before and after treatment.
Time frame: Baseline until 18 months from treatment initiation
CD19 cell count
CD19 cells will be measured in participants before and after treatment.
Time frame: Baseline until 18 months from treatment initiation
IgG level
IgG titers will be measured in participants before and after treatment.
Time frame: Baseline until 18 months from treatment initiation
IgA level
IgA titers will be measured in participants before and after treatment.
Time frame: Baseline until 18 months from treatment initiation
IgM level
IgM titers will be measured in participants before and after treatment.
Time frame: Baseline until 18 months from treatment initiation
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Oct 2031, 71 months after the start.
Of 31 phase 2 interventional studies under Immunoglobulin Light-chain Amyloidosis, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 89. This study's planned 71 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Teclistamab · Daratumumab and Hyaluronidase-fihj
Immunoglobulin Light-chain Amyloidosis →
Rajshekhar Chakraborty, MD